| Active Not Recruiting | Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION) NCT06460844 | Ray Therapeutics, Inc. | Phase 1 |
| Recruiting | Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retin NCT06375239 | Ray Therapeutics, Inc. | — |
| Withdrawn | The Dark-Adapted Retinal Function Response in Choroideremia (DARC) Study NCT05045703 | Duke University | N/A |
| Recruiting | A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitre NCT05282953 | Kiora Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Enrolling By Invitation | Longitudinal Study of a Bionic Eye NCT05158049 | Center for Eye Research Australia | — |
| Unknown | Structural and Functional Characterization of Rare Ocular Diseases NCT05258032 | Barcelona Macula Foundation | — |
| Completed | A Study to Assess Choroideremia (CHM) Health Outcomes NCT04750785 | Biogen | — |
| Completed | Natural Disease Progression in Participants With Choroideremia NCT04795206 | Biogen | — |
| Active Not Recruiting | Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia NCT04483440 | 4D Molecular Therapeutics | Phase 1 |
| Enrolling By Invitation | Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Trea NCT03584165 | NightstaRx Ltd, a Biogen Company | Phase 3 |
| Completed | Study of a Suprachoroidal Retinal Prosthesis NCT03406416 | Mobius Medical Pty Ltd. | N/A |
| Completed | Efficacy and Safety of BIIB111 for the Treatment of Choroideremia NCT03496012 | Biogen | Phase 3 |
| Completed | A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111 NCT03507686 | Biogen | Phase 2 |
| Terminated | "Natural History" Study of Choroideremia NCT02994368 | 4D Molecular Therapeutics | — |
| Completed | REP1 Gene Replacement Therapy for Choroideremia NCT02407678 | University of Oxford | Phase 2 |
| Completed | Compensation for Blindness With the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dyst NCT02670980 | Science Corporation | N/A |
| Completed | THOR - Tübingen Choroideremia Gene Therapy Trial NCT02671539 | STZ eyetrial | Phase 2 |
| Completed | Choroideremia Gene Therapy Clinical Trial NCT02553135 | Byron Lam | Phase 2 |
| Completed | Natural History of the Progression of Choroideremia Study NCT03359551 | NightstaRx Ltd, a Biogen Company | — |
| Completed | An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia NCT02077361 | University of Alberta | Phase 1 / Phase 2 |
| Completed | Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations NCT02341807 | Spark Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Inherited Retinal Degenerative Disease Registry NCT02435940 | Foundation Fighting Blindness | — |
| Recruiting | High Resolution Retinal Imaging NCT01866371 | University of Pennsylvania | — |
| Completed | Restoring Vision With the Intelligent Retinal Implant System (IRIS V1)in Patients With Retinal Dystrophy NCT01864486 | Science Corporation | N/A |
| Terminated | The Short-term Effects of Simvastatin on the Vision of Males Affected by Choroideremia NCT01654562 | University of Alberta | Phase 1 / Phase 2 |
| Completed | Pilot Study of a Suprachoroidal Retinal Prosthesis NCT01603576 | Center for Eye Research Australia | N/A |
| Completed | Gene Therapy for Blindness Caused by Choroideremia NCT01461213 | University of Oxford | Phase 1 / Phase 2 |
| Unknown | IRIS PILOT - Extended Pilot Study With a Retinal Implant System NCT00427180 | Intelligent Medical Implants GmbH | N/A |